Devon W. Edwards

Devon is a member of the New York Intellectual Property Law Association.

• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, February 2021
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, November 2020
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2020
• Willkie Obtains Significant Victory for Hospira in Pharmaceutical Patent Litigation, April 6, 2020
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2020
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2020
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2019
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2019
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2019
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2018
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2018
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2018
• The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2017
• Supreme Court Ruling in TC Heartland Revives Focus on the Corporate “Place of Business,” Willkie Client Memo (May 25, 2017)

• Belcher v. Hospira (epinephrine) – Achieved judgment of non-infringement, invalidity, and unenforceability of asserted patent on behalf of Hospira in Hatch-Waxman litigation in District of Delaware.
• Insurent Agency Corp. v. Hanover Insurance Co. – Achieved victory on summary judgment for Hanover on all claims in S.D.N.Y., including allegations of copyright infringement and trade secret misappropriation.
• Merck v. Amneal (mometasone furoate) – Successfully defended district court judgment of non-infringement for Amneal at the Federal Circuit in appeal of Hatch-Waxman action.